NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Organigram Global Inc. (OGI) Stock Analysis

Organigram Global Inc. (OGI) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OGI

$0.94

+$0.00 (+0.38%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OGI with… →

OGI Key Statistics

As of Oct 21, 2026
Trading
Open
$0.94
Previous Close
$0.94
Day's Range
0.92–0.95
52-Week Range
0.85–2.24
Volume
215.66K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.91
Valuation
Market Cap
$135.59M
P/E Ratio
2.19
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
39.19
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.44
EPS (ttm)Profit attributable to each share over the last twelve months.
0.43
Financials (FY)
Revenue (FY)
$259.18M+62.15%
Net Income (FY)
−$24.76M
Profit marginThe share of revenue left as profit after all costs and taxes.
28.02%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
144.15M
1-Year Return
−45.31%
Dividend and dates
Avg Volume
857.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OGI closed at $0.94, −45.31% over 1 year.

Organigram Global Inc. (OGI) has a market capitalization of $135.59M.

In fiscal 2025, OGI reported revenue of $259.18M.

OGI Stock Return by Calendar Year

Organigram Global Inc. (OGI) return since May 2019: what $10,000 became

1 year
$10,000 $5,469
−45.31%
5 years
$10,000 $964
−90.36%
Since May 2019
$10,000 $301
−96.99%

If you had invested $10,000 in Organigram Global Inc. (OGI) at the close on May 21, 2019, the earliest close on record here, it would have been worth $301 at the close on October 21, 2026: −96.99% in total, −37.63% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.01%
2025+4.35%
2024+22.90%
2023−59.06%
2022−54.29%
2021+31.58%
2020−45.71%
2019 (partial year)−68.63%

As of October 21, 2026.

OGI Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$259.18M−$24.76M−9.6%
2024$159.84M−$45.44M−28.4%
2022$145.81M−$14.28M−9.8%
2021$79.16M−$130.70M−165.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$259.18M$90.22M−$15.30M−$24.76M−9.6%
2024$159.84M$47.52M−$34.76M−$45.44M−28.4%
2022$145.81M$31.57M−$38.75M−$14.28M−9.8%
2021$79.16M−$28.40M−$72.84M−$130.70M−165.1%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

OGI Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricOGIDrug Manufacturers - Specialty & Generic medianvs median
P/E2.1920.310.1x the median
P/S ratio0.442.100.2x the median
Profit margin28.02%−8.14%36.2 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Organigram Global Inc. (OGI) is capitalised at $135.59M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 1,139 employees.

The 52-week range on file runs from $0.85 to $2.24. OGI last closed at $0.94 on October 21, 2026. That is $0.00 (+0.38%) against the previous close. The latest close sits 10.27% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $259.18M. Against the prior fiscal year total of $159.84M, that is a change of +62.15%. The same year closed with a net loss of $24.76M. The reported profit margin is 28.02%. That is 36.2 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 0.43.

Across the 4 fiscal years on file, revenue moves from $79.16M in 2021 to $259.18M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

OGI trades at a trailing price-to-earnings ratio of 2.19. That is 0.1 times the Drug Manufacturers - Specialty & Generic median of 20.31. On forward earnings the ratio is 39.19. The price-to-sales ratio is 0.44. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the total return is −45.31%. Across 5 years the annualized return works out at −37.37%. The reported beta is 1.91. Annualized volatility over the trailing 7 years is 81.89%.

Growth & Income

The record shows no dividend for OGI.

The strongest complete calendar year on file is 2021 at +31.58%; the weakest is 2023 at −59.06%. Of the 6 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −44.01%.

Peer Comparison

Organigram Global Inc. (OGI) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Organigram Global Inc. OGI $135.59M 2.2
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Organigram Global Inc. trades at a P/E of 2.2.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Organigram Global Inc.

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.

Visit website →